Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Tcg X
BioCentury | Mar 21, 2025
Finance
Maxion, Ampersand, Latigo, Arbor raise private rounds: Finance Report
Plus: SV Health Investors hits $250M goal for second Dementia Discovery Fund
BioCentury | Dec 13, 2024
Editor's Commentary
VC fundraising in a post-‘supercycle’ era: a Perspective
Some firms are no longer making their latest funds their largest; others may follow
BioCentury | Oct 22, 2024
Product Development
Newco trend watch: Clusters of launches point to areas undergoing derisking
Oligo delivery to the kidney, and two emerging use cases for T cell engagers, each get newcos; most with mega-
BioCentury | Oct 11, 2024
Finance
Upstream catches aftermarket updraft, as Camp4 IPO gets muted reception
BioCentury’s weekly Public Equity Report also includes financings by Crinetics, Scholar Rock, Immatics, Inhibikase and Vicore
BioCentury | Sep 26, 2024
Finance
Eyes on Europe: Asabys’ €180M fund, Genespire’s record series B
BioCentury’s weekly Venture Report also includes Arch’s latest fund, Flagship-backed Mirai, series Bs for Vicebio and 858, and more
BioCentury | Sep 20, 2024
Finance
Upstream enters IPO queue; Nuvalent follow-on balloons to $575M
Also in BioCentury’s weekly Public Equity Report: Ascendis follows up a data release with a $300M offering; BioAge proposes terms for listing
BioCentury | Sep 12, 2024
Finance
Venture Report: Big rounds for Candid, Superluminal, PanTera
Plus: Rounds for Radiant, Vironexis, Bambusa, OrsoBio and F2G
BioCentury | Aug 22, 2024
Finance
Venture Report: Megarounds for BridgeBio newco, Pathalys and the latest from Versant
$300M raise for rare disease company GondolaBio headlines the week’s biggest venture rounds
BioCentury | May 23, 2024
Finance
Venture Report: Versant revisits build-to-buy model with obesity play SixPeaks
Plus: Progentos’ launch; series B rounds for AltruBio, Pheon and Grey Wolf; a series A for Vienna-based Ygion; and more
BioCentury | Apr 5, 2024
Finance
Venture report: Nine-digit rounds for Obsidian, Alterome, Diagonal
Plus: Neurosterix launches with a potential competitor to the schizophrenia therapy developed by Karuna
Items per page:
1 - 10 of 22